Share

SARS CoV-2 seroprevalence among HIV-negative participants using tenofovir/emtricitabine- based PrEP in 2020 ' a sub-study of PREVENIR-ANRS and SAPRIS-Sero

Title
SARS CoV-2 seroprevalence among HIV-negative participants using tenofovir/emtricitabine- based PrEP in 2020 ' a sub-study of PREVENIR-ANRS and SAPRIS-Sero
Presenter
Constance Delaugerre
Authors
C. Delaugerre * (1), L. Assoumou (2), S. Maylin (3), M. Minier (3), A. Gabassi (3), M. Genin (2), L. Beniguel (2), J. Ghosn (4), X. de lamballerie (5), M. El Mouhebb (2), D. Costagliola (2), F. Carrat (2), J.-M. Molina (6), PREVENIR study Group
Institutions
(1) Hôpital Saint Louis, Université de Paris, Virologie, Paris, France, (2) Institut Pierre Louis d''Epidémiologie et de Santé Publique, Sorbonne Université, Paris, France, (3) Hôpital Saint Louis, Virologie, Paris, France, (4) Hôpital Bichat, Université de Paris, Maladies Infectieuses, Paris, France, (5) Unité des Virus Emergents, INSERM, Marseille, France, (6) Hôpital Saint Louis - Université de Paris, Maladies Infectieuses, Paris, France

BACKGROUND: Tenofovir (TDF) has shown activity on the SARS-CoV-2 RdR polymerase in vitro and in ferrets. There is controversy regarding the potential benefit of TDF to reduce SARS-CoV-2 infection or COVID-19-related morbidity. Our objective was to compare the seroprevalence rates of SARS CoV-2 IgG among male participants using TDF/FTC-based PrEP and matched controls.
METHODS: Male participants from the PREVENIR study conducted in Ile de France, who are receiving on demand or daily PrEP and with an available sample between May and October 2020 were included in this study. The Sapris-Sero study was a sub-study of the national Sapris cohort, with several wave of sampling from May 2020 after the end of the March-May lockdown. Male participants of the SAPRIS-Sero study living in Ile de France were matched to each PREVENIR participant on age ("± 5 years), socio-occupational category and date of sampling ("± 1 month). Odd Ratios (OR) of the comparison between the 2 studies was calculated using stratified logistic regression. SARS-CoV2 IgG anti S was measured using the Abbott SARS-CoV-2 IgG II Quant antibody test in PREVENIR and the Euroimmuns Anti-SARS-CoV-2 ELISA IgG test in SAPRIS-Sero.
RESULTS: In PREVENIR, 844 participants with a median (IQR) age of 38 (31 ' 45) years were matched to 844 participants of SAPRIS-Sero cohort, aged of 41 (35 ' 48) years. Matching was possible on the 3 variables for 729 participants. PrEP was on demand in 420 (49.8%) and daily in 424 (50.2%) individuals. For PREVENIR and SAPRIS-Sero cohorts, SARS CoV-2 IgG was negative in 753 (89.2%) and 738 (87.4%) subjects, low positive/undetermined in 4 (0.5%) and 28 (3.3%) and positive in 87 (10.3%) and 78 (9.2%), respectively. Considering low positive /undetermined as negative, OR was estimated as 1.13 (0.82-1.53). Sensitivity analyses (restricted to full matched samples and/or considering undetermined as positive) led to similar results.
CONCLUSIONS: Prevalence of SARS-CoV-2 IgG was similar in PrEP users and in a matched cohort in the Paris region after the COVID lockdown suggesting that TDF/FTC has no role in reducing SARS-CoV-2 acquisition.